Seres Therapeutics Files 8-K on Fiscal Year Change

TL;DR

Seres Therapeutics (MCRB) changed its fiscal year end to 12/31. Nothing else major.

AI Summary

Seres Therapeutics, Inc. filed an 8-K on April 8, 2024, reporting on events that occurred on April 4, 2024. The filing indicates a change in the company's fiscal year end to December 31st and includes information regarding the submission of matters to a vote of security holders and financial statements. The company is incorporated in Delaware and its principal executive offices are located in Cambridge, MA.

Why It Matters

This filing updates Seres Therapeutics' reporting structure, specifically its fiscal year end, which is important for investors tracking financial performance and for regulatory compliance.

Risk Assessment

Risk Level: low — The filing is primarily administrative, detailing changes to the company's fiscal year and standard reporting procedures, with no immediate financial or operational risks indicated.

Key Numbers

• 1231 — Fiscal Year End (The company has updated its fiscal year end to December 31st.)

Key Players & Entities

• Seres Therapeutics, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of Incorporation
• Cambridge, MA (location) — Principal Executive Offices
• April 4, 2024 (date) — Date of earliest event reported
• April 8, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — ich registered Common stock, par value $0.001 per share MCRB The Nasdaq Stock Mar

Filing Documents

• d798362d8k.htm (8-K) — 38KB
• d798362dex31.htm (EX-3.1) — 5KB
• 0001193125-24-089654.txt ( ) — 165KB
• mcrb-20240404.xsd (EX-101.SCH) — 3KB
• mcrb-20240404_lab.xml (EX-101.LAB) — 18KB
• mcrb-20240404_pre.xml (EX-101.PRE) — 11KB
• d798362d8k_htm.xml (XML) — 4KB

- Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers

Item 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 52,923,699 29,004,971 660,988 21,764,552 Item 4 - Approval of an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 240,000,000 to 360,000,000 shares. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 81,471,934 21,346,140 1,536,136 0 Item 5 - Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes at the time of the Annual Meeting to approve Item 4. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 83,248,729 19,390,195 1,715,286 0

– A stockholder proposal on Simple Majority Vote

Item 6 – A stockholder proposal on Simple Majority Vote. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 52,117,624 29,641,877 830,157 21,764,552 Based on the foregoing votes, the director nominees listed in Item 1 were elected and Items 2 through 6 were approved. Item9.01.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Certificate of Amendment to Restated Certificate of Incorporation of Seres Therapeutics, Inc., dated April 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERES THERAPEUTICS, INC. Date: April 8, 2024 By: /s/ Thomas J. DesRosier Name: Thomas J. DesRosier Title: Executive Vice President and Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR